Catalyst

Slingshot members are tracking this event:

Phase 2 data expected to be released for SHP607 study on retinopathy of prematurity

Source Link:
https://www.shire.com/newsroom/2016/february/shire-announces-full-year-2015-results

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
SHPG
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details SHP607 Phase 2 topline data in Retinopathy of Prematurity expected in mid-2016.  The study aims to "compare the severity of retinopathy of prematurity (ROP) among treated infants with an untreated control population, matched for gestational age at birth while confirming the dose of treatment is safe and efficacious".
http://www.shiretria...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Jun 30, 2016
Occurred Source:
https://www.shire.com/newsroom/2016/june/stemys
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Shp607, Phase 2 Data, Retinopathy Of Prematurity
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.